Bajaj Healthcare Limited has informed the Exchange about General Updates
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 10.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bajaj Healthcare reported FY2026 revenue of Rs. 6,110.31 crore, up 12.6% from Rs. 5,426.02 crore in FY2025. However, net profit dropped 60% to Rs. 157.66 lakh from Rs. 394.96 lakh previously due to a Rs. 332.47 lakh exceptional charge from reversal of technical know-how income related to a Middle East customer affected by regional instability. The auditors issued an unmodified opinion. The Board recommended a 30% dividend (Rs. 1.50 per share of Rs. 5 face value) for FY2025-26, subject to shareholder approval. The company also appointed new internal auditors (JCR & Co. LLP) and reappointed cost auditors (V.J. Talati & Co.) for FY2026-27. Cash and cash equivalents increased significantly to Rs. 872.35 lakh from Rs. 26.04 lakh due to equity warrant conversion proceeds.
The stock may face pressure as profit declined sharply despite revenue growth due to the one-time Middle East income reversal. The dividend provides some support to investors, while the company has raised capital through warrant conversion for debt repayment and capex.